



ASX ANNOUNCEMENT

CELLMID CAPITAL RAISING

SYDNEY, Monday 15 December 2014: Cellmid Limited (ASX: CDY) (the **Company**), is pleased to advise that it received commitments totalling approximately \$1.3 million, for new fully paid shares in the Company at 2.3c per Placement Share (the **Placement**).

The Placement was supported by new institutional and sophisticated investors as well as existing shareholders. Hawkesbury Partners acted as Lead Manager for the Placement.

The Company intends to apply the funds raised to progress its CAB102 program towards the planned phase I human clinical trials. This capital raising will also allow the Company to invest into commercial activities associated with its consumer health business.

Details of the Placement

Under the Placement, binding commitments have been received to subscribe for approximately 55 million Placement Shares at a price of 2.3 cents per Placement Share, representing approximately \$1.3 million. The issue price for the Placement Shares represents a:

- 17.9 % discount to the last closing price of the Company's shares on 10 December 2014
- 17.9 % to the 5 day volume weighted average price of the Company's shares.

The Placement was available to investors in Australia who qualified as professional or sophisticated investors under the requirements of the Corporations Act 2001 (Cth) and sophisticated and professional investors in select other jurisdictions. The Placement Shares are expected to be issued on or around Thursday, 18 December 2014 and will rank equally in all respects with existing ordinary shares on issue on the date of allotment. The Placement Shares will be issued in accordance with the approval of shareholders granted at the AGM on 10 October 2014.

End

Contact:

Maria Halasz, CEO

T +612 9221 6830

@mariahalasz

Cellmid Limited (ASX: CDY)

Cellmid is an Australian biotechnology company developing innovative novel therapies and diagnostic tests for inflammatory diseases and cancer. Cellmid holds the largest and most comprehensive portfolio of intellectual property related to midkine and midkine antagonists globally. The Company's most advanced development programs involve using its anti-midkine antibodies for the treatment of cancer and inflammatory diseases. In addition, Cellmid is commercialising midkine as a biomarker for cancer diagnosis. Elevated midkine concentration in the blood and other body fluids is strongly indicative of cancer. For further information please see www.cellmid.com.au.